CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Chardan’s 7th Annual Genetic Medicines Conference
Fireside Chat: Monday, October 2, 2023 at 4:00 pm ET
Location: The Westin New York Grand Central, New York, NY
A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com.
JonesTrading 2023 Healthcare Summit
October 10-11, 2023
Location: Eden Rock Miami Beach, Miami, FL
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Media & Investors
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$22.41 |
| Daily Change: | -1.70 -7.05 |
| Daily Volume: | 142,544 |
| Market Cap: | US$153.510M |
October 22, 2025 October 17, 2025 October 16, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
